<DOC>
	<DOCNO>NCT00050999</DOCNO>
	<brief_summary>The purpose study compare effectiveness two dose level ONTAK ( denileukin diftitox ) treat patient recurrent persistent cutaneous T-cell lymphoma .</brief_summary>
	<brief_title>Study ONTAK ( Denileukin Diftitox ) Cutaneous T-Cell Lymphoma ( CTCL ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>Histopathologically confirm recurrent persistent CTCL determine reference pathology lab ; Patient must 1 3 prior CTCL therapy . Repeated use agent consider 1 therapy unless part different combination regimen . Only 1 prior combination cytotoxic regimen permit . Topical systemic steroid consider therapy ; Interleukin2 receptor ( IL2R ) expression least 20 % tumor cell determine immunohistochemistry . Stage IA III disease unlikely progress first month study . Life expectancy least 12 month . Measurable evaluable disease . Lymph node involvement great LN2 . No CTCL involvement bone marrow . No active CNS disease , kidney liver disease , significant pulmonary disease , cardiac disease . No systemic infection ; Willingness randomize placebo treatment arm ; ECOG performance status 0 1 ; â€¢ Patients must previously receive treatment DAB389IL2 DAB486IL 2 ( previous candidate compound evaluate clinical setting ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>